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Group III metabotropic glutamate (mGlu) receptors mediate important neuroprotective
and anti-inflammatory effects. Stimulation of mGlu4 receptor reduces neuroinflammation
in a mouse model of experimental autoimmune encephalomyelitis (EAE) whereas
mGlu4 knockout mice display exacerbated EAE clinical scores. We now show that
mGlu4 receptors are expressed in oligodendrocytes, astrocytes and microglia in culture.
Oligodendrocytes express mGlu4 receptors only at early stages of maturation (O4
positive), but not when more differentiated (myelin basic protein, MBP positive).
Treatment of immature oligodendrocytes with the mGlu4 receptor agonist L-2-Amino-4-
phosphonobutyrate (L-AP4; 50 µM for 48 h) accelerates differentiation with enhanced
branching and earlier appearance of MBP staining. Oligodendrocyte death induced
by exposure to 1 mM kainic acid for 24 h is significantly reduced by a 30-min
pretreatment with L-AP4 (50 µM), an effect observed only in the presence of astrocytes,
mimicked by the specific mGlu4 receptor positive allosteric modulator N-Phenyl-7-
(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide (PHCCC) (30 µM) and prevented by
pretreatment with the mGlu4 receptor antagonist, cyclopropyl-4-phosphonophenylglycine
(CPPG) (100 µM). In astrocytes, mGlu4 receptor is the most expressed among group III
mGlu receptors, as by Quantitative real time PCR (QRT-PCR), and its silencing prevents
protective effects. Protection is also observed when conditioned medium (CM) from
L-AP4-pretreated astrocytes is transferred to oligodendrocytes challenged with kainic acid.
Transforming growth factor β (TGF-β) mediates the increased oligodendrocyte survival as
the effect of L-AP4 is mimicked by addition of 10 ng/ml TGF-β and prevented by incubation
with a neutralizing anti-TGF-β antibody. In contrast, despite the expression of mGlu4
receptor in resting and activated microglia, CM from L-AP4-stimulated microglia does not
modify kainate-induced oligodendrocyte toxicity. Our results suggest that mGlu4 receptors
expressed in astrocytes mediate enhanced survival of oligodendrocytes under conditions
of excitotoxicity.
Keywords: multiple sclerosis, experimental autoimmune encephalomyelitis, astrocytes, transforming growth
factor β, oligodendrocytes
INTRODUCTION
Oligodendrocyte damage is a critical step in neuroinflammation
occurring in demyelinating diseases such as multiple sclerosis
(MS; Lassmann, 1998). Oligodendrocytes express several glu-
tamate receptors including ionotropic glutamate receptors that
mediate excitotoxicity, but also metabotropic glutamate (mGlu)
receptors, G-protein-coupled receptors that are classified in three
different families depending on their pharmacological profile and
signaling pathway (Nicoletti et al., 2011). These include group
I (mGlu1 and mGlu5) receptors coupled to phosphoinositide
hydrolysis, group II (mGlu2 and mGlu3) and group III (mGlu4,
mGlu6, mGlu7, mGlu8) receptors, all negatively coupled to
adenylate cyclase (Conn and Pin, 1997).
Several mGlu receptors seem to play a role in neuroinflam-
mation and changes in their expression have been reported
in MS brain. Specifically, mGlu1 receptor shows an enhanced
axonal immunoreactivity (Geurts et al., 2003) and appears in
reactive microglia and astrocytes in MS white matter (Newcombe
et al., 2008). Similarly, mGlu2/3 receptors are markedly over-
expressed in astrocytes in acute and chronic active MS lesions
(Geurts et al., 2003), staining large reactive astrocytes as well
as small round cells, very likely glial progenitors (Newcombe
et al., 2008). More controversies exist regarding the expres-
sion of mGlu5 receptors that, however, are described to be
enhanced in reactive astrocytes of MS lesions (Geurts et al.,
2003). Finally, mGlu8 receptor immunoreactivity is increased
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predominantly in cells of the microglia/macrophage lineage
in actively demyelinating lesions and occasionally in reactive
astrocytes (Geurts et al., 2005), whereas mGlu4 receptor is over-
expressed in a selected population of reactive astrocytes localized
in the rim of chronic active lesions in MS brain (Geurts et al.,
2005).
Much attention has been focused on the involvement of group
III mGlu receptors in neuroinflammation since these receptors are
expressed in glial cells in vitro and their activation inhibits the
production of inflammatory chemokines (Besong et al., 2002),
the release of glutamate and superoxide (McMullan et al., 2012;
Mead et al., 2012) and reduces astroglial and microglial neuro-
toxicity (Taylor et al., 2003; Zhou et al., 2006; Pinteaux-Jones
et al., 2008). In addition, activation of group III mGlu receptors
reduces the disability score in mice with experimental autoim-
mune encephalomyelitis (EAE), an established animal model
of neuroinflammation and demyelination (Besong et al., 2002).
More importantly, mGlu4 receptors are expressed in peripheral
dendritic cells and mediate adaptive immunity (Fallarino et al.,
2010). mGlu4 receptor knockout mice are more vulnerable to
EAE and treatment of wild type animals with a mGlu4 receptor
enhancer reduces EAE by modulating the function of peripheral
T cells (Fallarino et al., 2010).
On the bases of this well described role of mGlu4 receptor in
the immune system, we asked whether the same receptor can also
mediate a protective effect in neuroinflammation directly at the
CNS. Hence, we have investigated in more detail the role of mGlu4
receptor in CNS cells, focusing specifically on its role in oligo-
dendrocyte survival. The effects of mGlu4 receptor activation
on different glial cell types and the impact on oligodendrocyte
survival have been analyzed.
MATERIALS AND METHODS
DRUGS AND REAGENTS
Cell culture plastics were provided by BD Falcon (Milan,
Italy.) Media, media supplements, serum, trypsin, poly-D-
Lysine, buffers and antibiotics were from Invitrogen Srl
(Milan, Italy). All components and growth factors for chem-
ically defined medium were from Sigma-Aldrich (St. Louis,
MO, USA). L-(+)-2-Amino-4-phosphonobutyric acid (L-AP4),
cyclopropyl-4-phosphonophenylglycine (CPPG), (-)-N-Phenyl-
7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide (PHC
CC) and kainic acid were from Tocris Cookson Ltd (North
Point, UK).
The following primary antibodies were used: mouse anti-O4
(1:40, Sigma-Aldrich), rabbit anti-mGluR4 (1:100, Millipore,
Billerica, MA, USA), mouse anti-glial fibrillary acidic protein
(GFAP; 1:300 Cell Signaling Technology, Beverly, MA, USA),
chicken anti-myelin basic protein (MBP; 1:500, Aves, Tigard,
OR, USA), chicken anti-Integrin α-M (1:40, Aves), mouse anti-
α-actin (1:5000, Sigma-Aldrich), rabbit anti platelet-derived
growth factor (PDGF) receptor (1:40, Santa Cruz) and mouse
anti-transforming growth factorβ1 (TGFβ1; R&D Systems, Min-
neapolis, MN, USA, 2 µg/ml for Western blot and flow cytom-
etry and 5 µg/ml as a neutralizing agent). The following
fluorochrome-conjugated secondary antibodies were used: phy-
coerithryn anti-mouse (1:400) from Santa Cruz Biotechnology
(Santa Cruz, CA, USA), Alexa-Fluor 546 anti-mouse and anti-
rabbit (1:500, Invitrogen), FITC anti-chicken (1:500, Aves) and
Texas red anti-chicken (1:100, Santa Cruz).
CELL CULTURES
All animal experimental procedures were carried out in accor-
dance with the directives of the Italian and EU regulations for
care and use of experimental animals (DL116/92) and approved
by the Italian Ministry of Health. Preparation of glial cell cul-
tures was carried out as previously described (Spampinato et al.,
2012) using 1- to 3-day-old Sprague-Dawley rats (Harlan, Udine,
Italy). After removal of meninges and isolation of cortices, cells
were dispersed by mechanical and enzymatic dissociation using a
solution of trypsin diluted in Hank’s Balanced Salt Solution. Cells
were plated onto 75 mm2 flasks, and maintained in Dulbecco’s
Modified Eagle’s medium (DMEM) supplemented with 10% fetal
calf serum (FCS), penicillin/streptomycin (100 U/ml-100 µg/ml)
and glutamine (2 mM). Confluent cultures at 10–12 DIV were
shaken for 2 h at 37◦C at 250 RPM to yield microglial cells
that were plated and maintained in DMEM with 10% FBS for
5–6 days. Flasks were then more vigorously (450 RPM) shaken for
eight additional hours to separate oligodendrocytes from astro-
cytes. Immature oligodendrocytes were maintained in DMEM-
F12 supplemented with penicillin/streptomycin, albumin from
bovine serum (BSA; 1%), glucose (1%), insulin (10 ng/ml), apo-
transferrin (10 ng/ml), putrescine (100 µM), glutamine (2 mM),
selenium (30 nM), progesterone (20 nM), PDGF (10 ng/ml),
fibroblast growth factors (FGF; 5 ng/ml), T3 (20 ng/ml), T4
(20 ng/ml) for 2 days. PDGF/FGF were removed on the day of
treatment. Adherent astrocytes were collected by trypsin diges-
tion, plated in DMEM supplemented with 10% FCS, and used for
experiments 6–8 days after re-plating.
IMMUNOSTAINING
Cells were fixed in 4% paraformaldehyde, permeabilized when
necessary with 0.1% Triton X-100 and saturated with 3% BSA.
Cells were then incubated with selective primary antibodies
then exposed to fluorochrome-conjugated secondary antibodies.
Quantitative analysis of oligodendrocyte morphology was carried
out on skeletonized images using a plugin for the freely avail-
able image-processing program ImageJ, as described (Arganda-
Carreras et al., 2010). This method, that is based on sequential
erosion of images, provides topological as well as metric informa-
tion, including number of branches and mean length of branches.
WESTERN BLOT
Cells were harvested in radioimmunoprecipitation assay
(RIPA) lysis buffer supplemented with anti-protease and
anti-phosphatase cocktail mixes and protein concentration was
determined with the Bradford reagent (all from Sigma-Aldrich).
Fifty to eighty micrograms of each sample were separated
by SDS-PAGE and transferred to nitrocellulose membranes
(Hybond ECL, Amersham, Milan, Italy). Membranes were
blocked with 3% non-fat milk for 30 min and processed
for immunodetection using specific horseradish peroxidase
(HRP)-conjugated secondary antibodies (Santa Cruz) and the
Immobilon Western Chemiluminescent HRP substrate detection
Frontiers in Cellular Neuroscience www.frontiersin.org January 2015 | Volume 8 | Article 462 | 2
Spampinato et al. Metabotropic glutamate receptor-4 and oligodendrocytes
system (Millipore). Densitometric analysis of band intensity was
carried out with the Image J Software developed by NIH and
freely available on the web.
PCR AND QRT-PCR
Total RNA was extracted from cortical astrocytes with RNeasy
Plus Mini Kit (Qiagen, Milan, Italy). Two microgram of total
RNA were used for cDNA synthesis, using the Superscript
Vilo Kit (Invitrogen) according to manufacturer’s instructions.
Two microliter of cDNA were used in each subsequent PCR
amplification, in an automatic thermal cycler (MJ Research),
using PCR master mix (Invitrogen) and corresponding oligos.
PCR amplification was conducted at 95◦C for 5 min followed
by 30 cycles at 94◦C and 55◦C for 45 s each and 72◦C for
1 min. The final extension step was 10 min at 72◦C. PCR
amplicons were visualized electrophoretically on a 2% agarose
gel in Tris-acetate/EDTA buffer after SYBR Green gel stain-
ing (Invitrogen). A single band was always detected. Lack of
contaminating genomic DNA was verified using no-RT con-
trols.
Quantitative real time PCR (QRT-PCR) was performed with
Rotor Gene Q using QuantiNova Sybr Green PCR Kit (Qiagen)
according to manufacturer’s instructions. The melting curves
obtained after each PCR amplification reaction confirmed the
specificity of the SYBR Green assays.
The following primers were used: GAPDH (F 5′-
GCCGCCTGGTCACCAGGGCTG-3′; R 5′-ATGGACTGTGGT
CATGAGCCC-3′); QuantiTect Primer Assay (Qiagen) for group
III mGluRs (mGluR4, cat. no. QT01081556; mGluR6, cat. no.
QT00187880; mGluR7, cat. no. QT00180502; mGluR8, cat. no.
QT01079960); S18 (F 5′- GAGGATGAGGTGGAACGTGT-3′; R
5′- GGACCTGGCTGTATTTTCCA-3′). The mGluR4/S18 ratio
was estimated using the DDCt method.
RNA SILENCING
Cultured astrocytes were transfected with lipofectamine 2000
(Invitrogen) and siRNA for mGluR4 (2.5 nM; FlexiTube, cat.
no. SI00266546, Qiagen). As control, parallel cultures were
transfected with siRNA Negative Control (cat. no. SI03650318,
Qiagen). Cells were exposed to lipofectamine and siRNA in Opti-
mem medium for 4 h at 37◦C, and let to recover in DMEM with
5% FBS for 24 h.
FLOW CYTOMETRY
Astrocytes and oligodendrocytes were gently harvested with
trypsin and fixed with paraformaldehyde 4%. Cells were
processed for immunostaining overnight at 4◦C with primary
antibodies, then exposed to fluorochrome-conjugated secondary
antibodies for 1 h at room temperature. Analyses were carried out
on a Beckman Coulter flow cytometer.
STATISTICAL ANALYSIS
Data shown are always mean ± SEM of 3–6 independent exper-
iments each run in triplicates or quadruplicates. When reported
in the text, n refers always to independent experiments. Data were
analyzed by one-way Anova followed by Newman-Keuls test for
significance. P < 0.05 was taken as the criterion for statistical
significance.
RESULTS
mGlu4 RECEPTOR MEDIATES OLIGODENDROCYTE DIFFERENTIATION
Immature oligodendrocytes were maintained in culture in
chemically defined medium supplemented with PDGF and
FGF and grown for 2–3 days. These cultures, O4-positive,
express mGlu4 receptor as detected by immunocytochemi-
cal analysis (Figure 1A). However, more mature oligoden-
drocytes, that are maintained in differentiating medium for
6–7 days prior to PDGF/FGF deprivation and that stain
positively for MBP (Figure 1B) do not express mGlu4
receptor.
Treatment of immature cultures with the group III mGlu
receptor agonist L-AP4, (50 µM, for 48 h) accelerates oligo-
dendrocyte differentiation as revealed by their morphology,
with enhanced branching and increased labeling with anti-MBP
(Figure 1D). Vehicle-treated cultures are shown in Figure 1C
for comparison. Quantitative analysis reveals that L-AP4 treat-
ment increases branch number (280 ± 42 vs. 100 ± 12%;
Figure 1E) whereas the mean length of branches is not modified
(100 ± 14 and 78 ± 13% for control and AP4-treated, respec-
tively; Figure 1F). Data are expressed as % change from control
values and are from two independent experiments in which six
fields in three samples were analyzed.
ASTROCYTES PLAY A MAIN ROLE IN mGlu4 RECEPTOR-MEDIATED
OLIGODENDROCYTE SURVIVAL
For toxicity studies, oligodendrocytes at early stages of differentia-
tion, and thus positively staining for both O4 and PDGF receptor,
were used. Exposure to 1 mM kainic acid for 24 h induces a
marked reduction of cell viability, detected by MTT assay, an effect
that is significantly more pronounced in pure oligodendrocyte
cultures (49.8 ± 2.2% of control) compared to cultures with a
low level of astrocyte contamination (77.2 ± 2.0% of control;
n = 3–4 independent experiments; Figure 2A). Characterization
of the cell population by flow cytometry, revealing respectively
<2% (Figure 2B, upper panel) and about 10% (Figure 2B, lower
panel) of GFAP-positive cells in the oligodendrocyte culture is
reported.
Pretreatment with L-AP4 (50 µM; added 30 min before kainic
acid) reduces kainate-induced toxicity. Interestingly, this effect is
observed only when oligodendrocytes are grown in the presence
of astrocytes (as described above, 86.0± 1.6% of control), but not
in oligodendrocyte cultures that do not allow astrocyte contami-
nation and that are more sensitive to kainate damage (46.5± 1.2%
of control; Figure 2A).
The protective effect of L-AP4 against kainate-induced
oligodendrocyte death is abrogated by the specific mGlu4
receptor antagonist CPPG (100 µM; 72.4 ± 0.6% vs. 79.5 ±
2.7% of control with L-AP4 and kainate; n = 3; Figure 2C)
and mimicked by the positive allosteric modulator of mGlu4
receptor, N-Phenyl-7-(hydroxyimino)cyclopropa[b]chromen-
1acarboxamide (PHCCC; 30 µM; 111 ± 1.6% of control;
Figure 2C) that, per se, non significantly, increases by 15% cell
viability (not shown).
Since the presence of astrocytes appears necessary for detec-
tion of mGlu4 receptor-mediated oligodendrocyte survival,
attention has been addressed to this glial cell type. Indeed,
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FIGURE 1 | Oligodendrocytes express mGlu4 receptor and respond to
L-AP4 with enhanced differentiation. Oligodendrocytes that stain
positively for O4 (red; A) express also mGlu4 receptors (green; A).
Co-labeling of mGlu4 receptor and MBP (B, right panel) reveals that more
mature oligodendrocytes (MBP immunopositive (B), left panel) do not
express mGlu4 receptor (B, middle panel). Treatment with the mGlu4
receptor agonist, L-AP4 (50 µM, for 48 h), accelerates oligodendrocyte
differentiation as revealed by their morphology (D), with enhanced initial
branching and increased labeling with MBP, as compared to control
conditions (C). Scale bar = 10 µm. Quantification of branching is reported
and expressed as number of branches (E) and length of branches (F). Both
values are expressed as % of control and each bar represents mean ± SE
of six different fields analyzed in three samples from two independent
experiments. *p < 0.05 vs. control by Student’s t-test.
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FIGURE 2 | The effect of L-AP4 on kainic acid-induced
oligodendrocyte death depends on astrocytes. Panel (A) reports
the different response of a 24 h treatment with 1 mM kainic acid
(KA) in pure oligodendrocyte cultures (− astrocytes) or in
oligodendrocyte cultures containing a low percentage of astrocytes
(+ astrocytes). Group III mGlu receptor agonist, L-AP4 (50 µM),
was added, 30 min before treatment with kainic acid (A).
Oligodendrocyte viability was measured by the MTT proliferation
assay. In (B), representative plots of the characterization of cell
population showing 1.8% (upper panel) and 7.9% (lower panel)
GFAP immunopositive cells and more than 90 and 80%,
respectively, PDGF-R expressing cells, as by flow cytometric
analysis. In (C), the effect of a 15 min pre-treatment with the
selective mGlu4 receptor antagonist CPPG (100 µM) on L-AP4
reduction of kainic acid-induced oligodendrocyte death. The last bar
on the right shows the effect of a 24 h treatment with the positive
allosteric modulator of mGlu4 receptor, PHCCC (30 µM for 24 h),
on kainate toxicity. Data in (A) and (C) are mean ± SE of three to
four independent experiments, with four replicates per treatment
group. *p < 0.05 vs. control, #p < 0.05 between indicated groups
and §p < 0.05 vs. kainic acid by one way ANOVA, followed by
Newman-Keuls multiple comparison test.
mGlu4 receptor is present in astrocytes cultured under basal
conditions and its expression is significantly increased in astro-
cytes activated by exposure to LPS (1 µg/ml for 48 h), as
shown by western blot analysis (124 ± 5% of control; n =
3; Figure 3A). Similarly, immunocytochemical analysis shows
several cells with intense mGlu4 receptor immunolabeling upon
LPS treatment (Figure 3B). Transfer of conditioned medium
(CM) from astrocytes, exposed for 2 h to L-AP4 (50 µM),
before washing and medium collection for the following 18 h,
reduces kainate-induced oligodendrocyte toxicity. This effect
is already present under basal conditions, but is more pro-
nounced after transfer of CM from LPS-activated astrocytes
(84.6 ± 0.7 and 90.7 ± 2.6% of control, respectively, n = 3;
Figure 3C). The experimental paradigm in this case is the
same described above, but astrocytes are activated by expo-
sure to LPS for a 48 h period that includes the 2 + 18 h
of L-AP4 treatment and CM collection, respectively. The effect
of L-AP4 is prevented by pre-treatment of astrocytes with the
mGlu4 receptor antagonist, CPPG (79.2 ± 1.9%; Figure 3C),
that, per se, is devoid of any effect. Since L-AP4 is known
to activate all class III mGlu receptors and to further sup-
port the involvement of mGlu4 subtype, the expression of
mGlu4, mGlu6, mGlu7 and mGlu8 receptors in astrocytes has
been assessed by QRT-PCR. As shown in Figure 4A, astro-
cytes, in our culture conditions, express mGlu4 receptor and
only very low levels of mGlu7 receptor, while mGlu6 and
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FIGURE 3 | mGlu4 receptor is expressed in astrocytes and mediates
enhanced oligodendrocyte viability. mGlu4 receptor expression in
cultured astrocytes is enhanced by exposure for 48 h to LPS (1 µg/ml), as
revealed by western blot analysis (A) and immunocytochemistry (B).
Representative bands of mGlu4 and α-tubulin are reported and bars
showing densitometry result from three independent determinations (A).
Co-immunostaining for mGlu4 receptor (green) and GFAP (red) is shown
(B). In (C), assessment of the viability of oligodendrocytes challenged with
kainic acid (1 mM for 24 h) after transferring of conditioned medium (CM)
obtained from astrocytes, under basal or LPS-stimulated conditions,
exposed for 2 h, prior to washing and medium collection for the following
18 h, to L-AP4 (50 µM) and the mGlu4 receptor antagonist CPPG (100 µM).
Data are mean ± SE of three independent experiments, each run in
quadruplicates. *p < 0.05 vs. all other conditions by Student’s t-test (A) and
one-way ANOVA followed by Newman-Keuls test (C). Scale bar = 20 µm.
mGlu8 receptors are undetectable (representative data from
one experiment run in triplicates are shown). Data were con-
firmed by gel electrophoresis following RT-PCR (not shown).
Furthermore, silencing of mGlu4 receptor, that yields about
a 40% reduction of its expression, as detected by QRT-PCR
(Figure 4B), dramatically affects the ability of CM from L-AP4-
treated astrocytes to protect oligodendrocytes against kainate
toxicity (65.2 ± 3.6 and 62.6 ± 3.9% vs. 84.9 ± 1.1 and
61.2 ± 4.2% for kainate and L-AP4 vs. kainate alone, under
silencing and non-silencing conditions, respectively; n = 4;
Figure 4C).
TRANSFORMING GROWTH FACTOR β1 (TGF-β) IS A MEDIATOR OF
mGlu4 RECEPTOR-INDUCED OLIGODENDROCYTE SURVIVAL
In order to identify soluble factors released by astrocytes respon-
sible for the observed protective effect, attention was focused
on TGF-β1. Treatment with TGF-β1 (10 ng/ml) for 24 h pro-
tects in fact oligodendrocytes against kainate-induced cell death
and simultaneous treatment of oligodendrocytes with 50 µM
L-AP4 and 10 ng/ml TGF-β1 produces a non additive effect
(71.4 ± 2.5% for kainate alone vs. 88.8 ± 2.7, 87.1 ± 2.0,
88.8 ± 3.4% for kainate plus L-AP4, TGFβ1, and L-AP4 and
TGFβ1, respectively; n = 6; Figure 5A). Exposure of astro-
cytes to 50 µM L-AP4 for 24 h increases the expression of
TGF-β1 as shown by western blot analysis (Figure 5B). Sim-
ilarly, flow cytometry reveals that the intracellular content of
TGF-β1, measured in the presence of brefeldin (1 µg/ml), is
increased upon exposure of LPS-pretreated astrocytes to L-AP4
for 6 h (50.6 ± 3.0 vs. 40.0 ± 4.0; n = 3; Figure 5C). The
6 h time point was chosen in order to detect initial accumula-
tion of TGFβ1 following AP4 stimulation, trying to avoid too
long exposure to brefeldin that may be toxic to astrocytes. To
ascertain whether an enhanced release of TGF-β1 from astro-
cytes could account for the protective effect of L-AP4, kainate
toxicity was analyzed in oligodendrocytes exposed to L-AP4-
treated astrocyte CM, in the presence of a neutralizing anti-TGF-
β1 antibody (5 µg/ml), during kainate exposure. Under these
conditions, a significant reduction of L-AP4 protective effect
is observed (72.0 ± 4.8 vs. 89.0 ± 2.8% of control; n = 4;
Figure 5D).
MICROGLIA IS NOT INVOLVED IN THE PROTECTIVE EFFECT OF L-AP4 ON
KAINATE-INDUCED OLIGODENDROCYTE DEATH
The role of microglia as a potential target of L-AP4 effect was ana-
lyzed in microglial cultures, under resting and LPS-activated con-
ditions. mGlu4 receptor is expressed in microglia independently
of the state of activation, as shown by co-immunostaining with
anti-mGlu4 receptor and anti-integrin, a marker of microglia
(Figure 6A). However, transfer of L-AP4-treated CM from resting
and activated microglia does not modify oligodendrocyte viability
(n = 3; Figure 6B).
DISCUSSION
A role for mGlu receptors in demyelinating diseases has long
been suggested and has found support mainly in descriptive
studies reporting enhanced expression of mGlu receptors in
MS lesions (Geurts et al., 2003, 2005; Newcombe et al., 2008),
but also in in vivo studies showing a protective effect of drugs
acting on mGlu receptors in EAE animals (Besong et al.,
2002; Fazio et al., 2008; Fallarino et al., 2010). In this regard,
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FIGURE 4 | L-AP4 acts on astrocytic mGlu4 receptor to protect
oligodendrocyte against kainate toxicity. Expression of group III mGlu
receptors, mGlu4, mGlu6, mGlu7 and mGlu8 receptors, was analyzed in
astrocytes by QRT-PCR (A). Expression of mGlu4 receptor after transfection
of cultured astrocytes with mGlu4 receptor siRNA (siRNA mGluR4) is shown
and compared to expression in astrocytes exposed to siRNA negative control
(siRNA Neg; (B)). In (C), the effect of CM from astrocytes treated with L-AP4
following silencing of mGlu4 receptor (siRNA mGlu4) or its negative control
(siRNA Neg) on kainate-induced oligodendrocyte death. In (A), data are
representative of several independent assays each run in triplicates. Data in
(B) and (C) are mean ± SE from four independent determinations. * p < 0.05
vs. respective control; §< 0.05 vs. kainate alone. A t-test and one-way
ANOVA plus Newman-Keuls test were applied to detect statistically
significant differences in (B) and (C), respectively.
particularly interesting is the involvement of mGlu4 receptor,
whose stimulation by L-AP4 results in improved recovery rate
from EAE, whereas treatment with the mGlu4 receptor positive
allosteric modulator (PAM), perhydrocyclopentanophenanthrene
(PHCPP), reduces the frequency and severity of relapses in EAE
mice (Fallarino et al., 2010). More recently, cinnabarinic acid,
that acts as an orthosteric agonist of mGlu4 receptor (Fazio
et al., 2012), was shown to exert protective activity against EAE
by modulating immune function (Fazio et al., 2014). In addi-
tion, EAE appears more severe in mice lacking mGlu4 recep-
tor, further supporting a main role for this receptor subtype
in the demyelinating process. Of note, the work by Fallarino
et al. (2010) demonstrated that mGlu4 receptor expressed in
peripheral dendritic cells mediates immunoregulatory effects,
affecting T cell development and adaptive immunity. In the
present study we have extended the analysis of the role of mGlu4
receptors to glial cells and show that this receptor is expressed
in astrocytes, oligodendrocytes and microglia. However, activa-
tion of astrocytic mGlu4 receptor appears primarily involved
in enhanced survival of oligodendrocytes exposed to an exci-
totoxic challenge. Hence the ability of mGlu4 receptor ligands
to affect neuroinflammation acting on immune system cells,
is complemented with the present data showing an astrocyte-
mediated effect on oligodendrocyte survival. In our opinion,
this observation deserves great attention as mGlu4 receptor is
identified as a novel target able to mediate various effects, at
different sites, to protect from demyelination. Interestingly, in
fact, other pharmacological approaches, such as antagonists of
ionotropic glutamate receptors, have shown increased oligoden-
drocyte survival, but no effect on neuroinflammation (Pitt et al.,
2000).
Expression of mGlu4 receptor in oligodendrocytes has already
been demonstrated and appears developmentally regulated (Deng
et al., 2004), consistent with a role for this receptor in oligoden-
drocyte differentiation. Accordingly, activation of mGlu4 receptor
by L-AP4 results in earliest appearance of a differentiated phe-
notype, with enhanced branching and MBP staining, an effect
that is evident up to 48 h after treatment, but not thereafter,
when the level of differentiation is comparable in control and
L-AP4-treated cultures. Interestingly, a detailed analysis of branch
formation reveals increased sprouting by mGlu4 receptor stim-
ulation correlates with increased number of branches, but the
ability of oligodendrocytes to increase their branch length is not
modified.
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FIGURE 5 | TGF-β1 is involved in the protective effect of L-AP4 against
kainate-induced oligodendrocyte death. Oligodendrocytes were treated
with TGF-β1 (10 ng/ml), L-AP4 (50 µM) or both, 30 min prior to exposure to
kainic acid (1 mM for 24 h). Cell viability was assessed by the MTT assay (A).
TGF-β1 expression in astrocytes assessed by western blot analysis under
basal and L-AP4-stimulated conditions (B). The intracellular content of TGF-β1,
assessed by flow cytometry in astrocytes exposed to LPS (0.1 µg/ml for 24 h)
and treated with 50 µM L-AP4 for 6 h in the presence of brefeldin (C). Mean
fluorescence intensity of all positive events is reported. A representative plot
showing basal (empty histogram) and L-AP4-treated (filled histogram), TGF-β1
positive cells is also shown (C). In (D), oligodendrocyte viability after
exposure to kainic acid (1 mM for 24 h) assessed in the presence of
anti-TGF-β1 antibody (5 µg/ml), after transferring of CM obtained from
astrocytes activated with LPS (1 µg/ml for 24 h) and treated with L-AP4
(50 µM) for 2 h prior to medium collection for 18 h. Data are mean ± SE of
4–6 independent experiments, each with three to four replicates. *p < 0.05
vs. respective control and **p < 0.05 vs. kainic acid (vhl) in a and vs. all other
kainic acid-treated conditions (vhl; aTGF-β1; L-AP4 + aTGF-β1) in (D).
Significance was assessed by ANOVA and Newman-Keuls test. In (B) and (C)
a Student’s t-test was applied.
Despite its expression in oligodendrocytes, astrocytic mGlu4
receptor appears necessary to protect oligodendrocytes against
the excitotoxic insult. The strict interplay between astrocytes
and oligodendrocytes is supported by the observation that
kainate-induced toxicity is attenuated by stimulation of mGlu4
receptor only in a mixed culture containing oligodendrocytes
and astrocytes, but no effect is observed when L-AP4 acts
directly on oligodendrocytes. Such a protective effect is achieved
also when transferring CM from L-AP4-stimulated astrocytes,
under basal conditions, but more effectively, after activation
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FIGURE 6 | Lack of effect of L-AP4-treated microglia CM on
oligodendrocyte survival. mGlu4 receptor expression in microglia under
resting conditions (vhl) or upon exposure to LPS (0.1 µg/ml) for 48 h as
revealed by immunocytochemistry (A). Microglia cells were labeled with an
antibody against the specific microglia marker integrin. In (B),
oligodendrocyte survival after 24 h exposure to kainic acid (1 mM for 24 h) is
not modified by transferring of CM from microglia, under resting or
LPS-activated conditions, treated or not with L-AP4, 50 µM for 2 h, prior to
medium collection for additional 18 h. Bars represent mean ± SE from two
separate experiments. Scale bar = 10 µm.
with LPS. Of note, under these conditions, mGlu4 recep-
tor expression is slightly upregulated, suggesting a function
for this receptor in those circumstances that produce astro-
cyte reactivity. Activation of mGlu receptors, including mGlu4,
in astrocytes, is reported to cause neuroprotection (Yao
et al., 2005; Zhou et al., 2006; Corti et al., 2007) and
here we show that astrocytes mediate also mGlu4 receptor-
enhanced survival of oligodendrocytes. This is consistent with
the greater toxicity caused by kainate in pure oligodendro-
cyte cultures, whereas the presence of astrocytes is per se
protective.
It is then plausible that soluble factors released by astrocytes
mediate L-AP4-increased oligodendrocyte viability. In this regard,
our attention has focused specifically on TGFβ1, due to the main
role played by this growth factor in astrocyte-mediated neuropro-
tection (Bruno et al., 1998; Brionne et al., 2003; Vivien and Ali,
2006; Caraci et al., 2012). We show here that TGFβ1 is increased
upon L-AP4 activation, protects oligodendrocytes from kainate-
induced toxicity and this effect is attenuated in the presence of
a neutralizing anti-TGFβ1 antibody. Consistent with this obser-
vation, TGFβ1 is increased by cinnabarinic acid treatment in
brain infiltrating leukocytes of wild type, but not, mGlu4 receptor
knockout EAE animals (Fazio et al., 2014). The role of TGFβ1
in neuroinflammation is however rather controversial. In fact,
the reported amelioration of clinical symptoms of EAE following
TGFβ1 treatment (Johns et al., 1991; Kuruvilla et al., 1991),
the enhanced disease severity following administration of anti-
TGFβ1 neutralizing antibodies (Johns and Sriram, 1993), and the
protection against EAE induction (Cautain et al., 2001; Blazevski
et al., 2013) are counterbalanced by the observation that TGFβ1 is
overexpressed in the early phases of EAE, long before the appear-
ance of clinical signs, and may create a permissive environment
for T cell infiltration and the onset of autoimmune inflammation
(Luo et al., 2007). Our data demonstrate that TGFβ1 production
induced by mGlu4 receptor stimulation protects oligodendrocyte
against an excitotoxic insult, further reinforcing the concept that
TGFβ1 effects can be site-specific and are protective when directed
to CNS cells. To our knowledge, no evidence correlates TGFβ1
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to oligodendrocyte viability, with the exception of the reported
TGFβ1-induced apoptosis in murine OLI-neu cell line (Schuster
et al., 2002; Schulz et al., 2008), a cellular model very different
from the primary oligodendrocytes used in the present study.
Finally, mGlu4 receptors are expressed in microglia and
their stimulation does not modify the viability of oligoden-
drocytes undergoing excitotoxicity, at least in our experi-
mental conditions. It has been previously reported in fact
that L-AP4 reduces microglial neurotoxicity (Pinteaux-Jones
et al., 2008) and prevents inhibition of microglial-induced
oligodendrocyte precursor cell proliferation (Taylor et al.,
2010). Interestingly, however, L-AP4 was shown to reduce the
inflammatory response (Taylor et al., 2003), and to decrease
MHC-class II immunostaining in the spinal cord of MBP
immunized rats (Besong et al., 2002). This suggests a pro-
tective role of L-AP4 during the inflammatory response, as
MHC-class II positive microglia cells are present in EAE
and peak at the onset of clinical symptoms (Murphy et al.,
2010).
In conclusion, the present data demonstrate that mGlu4
receptors exert different functions in glial cell types, including
enhanced oligodendrocyte viability, an effect that appears well
in line with the reported neuroprotective effects ascribed to this
receptor (reviewed in Williams and Dexter, 2013). Importantly,
the effects mediated by mGlu4 receptors expressed on glial cells
appear to be complementary to those exerted in the immune
system (Fallarino et al., 2010), further confirming that targeting
mGlu4 receptors may be effective to contrast neuroinflammatory
conditions.
ACKNOWLEDGMENTS
This work was supported by a PRIN2009 grant from the Italian
Ministry of University.
REFERENCES
Arganda-Carreras, I., Fernandez-Gonzalez, R., Munoz-Barrutia, A., and Ortiz-De-
Solorzano, C. (2010). 3D reconstruction of histological sections: application to
mammary gland tissue. Microsc. Res. Tech. 73, 1019–1029. doi: 10.1002/jemt.
20829
Besong, G., Battaglia, G., D’Onofrio, M., Di Marco, R., Ngomba, R. T., Storto, M.,
et al. (2002). Activation of group III metabotropic glutamate receptors inhibits
the production of RANTES in glial cell cultures. J. Neurosci. 22, 5403–5411.
Blazevski, J., Petkovic, F., Momcilovic, M., Jevtic, B., Miljkovic, D., and Mostarica
Stojkovic, M. (2013). High interleukin-10 expression within the central nervous
system may be important for initiation of recovery of Dark Agouti rats from
experimental autoimmune encephalomyelitis. Immunobiology 218, 1192–1199.
doi: 10.1016/j.imbio.2013.04.004
Brionne, T. C., Tesseur, I., Masliah, E., and Wyss-Coray, T. (2003). Loss of TGF-beta
1 leads to increased neuronal cell death and microgliosis in mouse brain. Neuron
40, 1133–1145. doi: 10.1016/s0896-6273(03)00766-9
Bruno, V., Battaglia, G., Casabona, G., Copani, A., Caciagli, F., and Nicoletti, F.
(1998). Neuroprotection by glial metabotropic glutamate receptors is mediated
by transforming growth factor-beta. J. Neurosci. 18, 9594–9600.
Caraci, F., Battaglia, G., Sortino, M. A., Spampinato, S., Molinaro, G., Copani,
A., et al. (2012). Metabotropic glutamate receptors in neurodegenera-
tion/neuroprotection: still a hot topic? Neurochem. Int. 61, 559–565. doi: 10.
1016/j.neuint.2012.01.017
Cautain, B., Damoiseaux, J., Bernard, I., van Straaten, H., van Breda Vriesman, P.,
Boneu, B., et al. (2001). Essential role of TGF-beta in the natural resistance to
experimental allergic encephalomyelitis in rats. Eur. J. Immunol. 31, 1132–1140.
doi: 10.1002/1521-4141(200104)31:4<1132::aid-immu1132>3.3.co;2-e
Conn, P. J., and Pin, J. P. (1997). Pharmacology and functions of metabotropic
glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 37, 205–237. doi: 10.
1146/annurev.pharmtox.37.1.205
Corti, C., Battaglia, G., Molinaro, G., Riozzi, B., Pittaluga, A., Corsi, M., et al.
(2007). The use of knock-out mice unravels distinct roles for mGlu2 and
mGlu3 metabotropic glutamate receptors in mechanisms of neurodegenera-
tion/neuroprotection. J. Neurosci. 27, 8297–8308. doi: 10.1523/jneurosci.1889-
07.2007
Deng, W., Wang, H., Rosenberg, P. A., Volpe, J. J., and Jensen, F. E. (2004).
Role of metabotropic glutamate receptors in oligodendrocyte excitotoxicity and
oxidative stress. Proc. Natl. Acad. Sci. U S A 101, 7751–7756. doi: 10.1073/pnas.
0307850101
Fallarino, F., Volpi, C., Fazio, F., Notartomaso, S., Vacca, C., Busceti, C.,
et al. (2010). Metabotropic glutamate receptor-4 modulates adaptive immu-
nity and restrains neuroinflammation. Nat. Med. 16, 897–902. doi: 10.1038/
nm.2183
Fazio, F., Lionetto, L., Molinaro, G., Bertrand, H. O., Acher, F., Ngomba, R. T.,
et al. (2012). Cinnabarinic acid, an endogenous metabolite of the kynurenine
pathway, activates type 4 metabotropic glutamate receptors. Mol. Pharmacol. 81,
643–656. doi: 10.1124/mol.111.074765
Fazio, F., Notartomaso, S., Aronica, E., Storto, M., Battaglia, G., Vieira, E., et al.
(2008). Switch in the expression of mGlu1 and mGlu5 metabotropic glutamate
receptors in the cerebellum of mice developing experimental autoimmune
encephalomyelitis and in autoptic cerebellar samples from patients with multi-
ple sclerosis. Neuropharmacology 55, 491–499. doi: 10.1016/j.neuropharm.2008.
06.066
Fazio, F., Zappulla, C., Notartomaso, S., Busceti, C., Bessede, A., Scarselli, P.,
et al. (2014). Cinnabarinic acid, an endogenous agonist of type-4 metabotropic
glutamate receptor, suppresses experimental autoimmune encephalomyelitis
in mice. Neuropharmacology 81, 237–243. doi: 10.1016/j.neuropharm.2014.
02.011
Geurts, J. J., Wolswijk, G., Bo, L., Redeker, S., Ramkema, M., Troost, D., et al. (2005).
Expression patterns of group III metabotropic glutamate receptors mGluR4 and
mGluR8 in multiple sclerosis lesions. J. Neuroimmunol. 158, 182–190. doi: 10.
1016/j.jneuroim.2004.08.012
Geurts, J. J., Wolswijk, G., Bo, L., van der Valk, P., Polman, C. H., Troost, D.,
et al. (2003). Altered expression patterns of group I and II metabotropic gluta-
mate receptors in multiple sclerosis. Brain 126, 1755–1766. doi: 10.1093/brain/
awg179
Johns, L. D., Flanders, K. C., Ranges, G. E., and Sriram, S. (1991). Successful
treatment of experimental allergic encephalomyelitis with transforming growth
factor-beta 1. J. Immunol. 147, 1792–1796.
Johns, L. D., and Sriram, S. (1993). Experimental allergic encephalomyelitis:
neutralizing antibody to TGF beta 1 enhances the clinical severity of the disease.
J. Neuroimmunol. 47, 1–7. doi: 10.1016/0165-5728(93)90278-7
Kuruvilla, A. P., Shah, R., Hochwald, G. M., Liggitt, H. D., Palladino, M. A., and
Thorbecke, G. J. (1991). Protective effect of transforming growth factor beta 1
on experimental autoimmune diseases in mice. Proc. Natl. Acad. Sci. U S A 88,
2918–2921. doi: 10.1073/pnas.88.7.2918
Lassmann, H. (1998). Neuropathology in multiple sclerosis: new concepts. Mult.
Scler. 4, 93–98. doi: 10.1177/135245859800400301
Luo, J., Ho, P. P., Buckwalter, M. S., Hsu, T., Lee, L. Y., Zhang, H., et al. (2007).
Glia-dependent TGF-beta signaling, acting independently of the TH17 pathway,
is critical for initiation of murine autoimmune encephalomyelitis. J. Clin. Invest.
117, 3306–3315. doi: 10.1172/jci31763
McMullan, S. M., Phanavanh, B., Li, G. G., and Barger, S. W. (2012). Metabotropic
glutamate receptors inhibit microglial glutamate release. ASN Neuro 4:e00094.
doi: 10.1042/an20120044
Mead, E. L., Mosley, A., Eaton, S., Dobson, L., Heales, S. J., and Pocock, J. M.
(2012). Microglial neurotransmitter receptors trigger superoxide production
in microglia; consequences for microglial-neuronal interactions. J. Neurochem.
121, 287–301. doi: 10.1111/j.1471-4159.2012.07659.x
Murphy, A. C., Lalor, S. J., Lynch, M. A., and Mills, K. H. (2010). Infiltration of
Th1 and Th17 cells and activation of microglia in the CNS during the course
of experimental autoimmune encephalomyelitis. Brain Behav. Immun. 24, 641–
651. doi: 10.1016/j.bbi.2010.01.014
Newcombe, J., Uddin, A., Dove, R., Patel, B., Turski, L., Nishizawa, Y., et al. (2008).
Glutamate receptor expression in multiple sclerosis lesions. Brain Pathol. 18, 52–
61. doi: 10.1111/j.1750-3639.2007.00101.x
Frontiers in Cellular Neuroscience www.frontiersin.org January 2015 | Volume 8 | Article 462 | 10
Spampinato et al. Metabotropic glutamate receptor-4 and oligodendrocytes
Nicoletti, F., Bockaert, J., Collingridge, G. L., Conn, P. J., Ferraguti, F., Schoepp,
D. D., et al. (2011). Metabotropic glutamate receptors: from the workbench
to the bedside. Neuropharmacology 60, 1017–1041. doi: 10.1016/j.neuropharm.
2010.10.022
Pinteaux-Jones, F., Sevastou, I. G., Fry, V. A., Heales, S., Baker, D., and Pocock, J. M.
(2008). Myelin-induced microglial neurotoxicity can be controlled by microglial
metabotropic glutamate receptors. J. Neurochem. 106, 442–454. doi: 10.1111/j.
1471-4159.2008.05426.x
Pitt, D., Werner, P., and Raine, C. S. (2000). Glutamate excitotoxicity in a model of
multiple sclerosis. Nat. Med. 6, 67–70. doi: 10.1038/71555
Schulz, R., Vogel, T., Dressel, R., and Krieglstein, K. (2008). TGF-beta superfamily
members, ActivinA and TGF-beta1, induce apoptosis in oligodendrocytes by
different pathways. Cell Tissue Res. 334, 327–338. doi: 10.1007/s00441-008-
0714-5
Schuster, N., Bender, H., Philippi, A., Subramaniam, S., Strelau, J., Wang, Z., et al.
(2002). TGF-beta induces cell death in the oligodendroglial cell line OLI-neu.
Glia 40, 95–108. doi: 10.1002/glia.10110
Spampinato, S. F., Molinaro, G., Merlo, S., Iacovelli, L., Caraci, F., Battaglia, G.,
et al. (2012). Estrogen receptors and type 1 metabotropic glutamate receptors
are interdependent in protecting cortical neurons against beta-amyloid toxicity.
Mol. Pharmacol. 81, 12–20. doi: 10.1124/mol.111.074021
Taylor, D. L., Diemel, L. T., and Pocock, J. M. (2003). Activation of microglial
group III metabotropic glutamate receptors protects neurons against microglial
neurotoxicity. J. Neurosci. 23, 2150–2160.
Taylor, D. L., Pirianov, G., Holland, S., McGinnity, C. J., Norman, A. L., Reali, C.,
et al. (2010). Attenuation of proliferation in oligodendrocyte precursor cells by
activated microglia. J. Neurosci. Res. 88, 1632–1644. doi: 10.1002/jnr.22335
Vivien, D., and Ali, C. (2006). Transforming growth factor-beta signalling in brain
disorders. Cytokine Growth Factor Rev. 17, 121–128. doi: 10.1016/j.cytogfr.2005.
09.011
Williams, C. J., and Dexter, D. T. (2013). Neuroprotective and symptomatic effects
of targeting group III mGlu receptors in neurodegenerative disease. J. Neu-
rochem. 129, 4–20. doi: 10.1111/jnc.12608
Yao, H. H., Ding, J. H., Zhou, F., Wang, F., Hu, L. F., Sun, T., et al.
(2005). Enhancement of glutamate uptake mediates the neuroprotection
exerted by activating group II or III metabotropic glutamate receptors
on astrocytes. J. Neurochem. 92, 948–961. doi: 10.1111/j.1471-4159.2004.
02937.x
Zhou, F., Yao, H. H., Wu, J. Y., Yang, Y. J., Ding, J. H., Zhang, J., et al. (2006).
Activation of group II/III metabotropic glutamate receptors attenuates LPS-
induced astroglial neurotoxicity via promoting glutamate uptake. J. Neurosci.
Res. 84, 268–277. doi: 10.1002/jnr.20897
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 24 October 2014; accepted: 18 December 2014; published online: 14 January
2015.
Citation: Spampinato SF, Merlo S, Chisari M, Nicoletti F and SortinoMA (2015) Glial
metabotropic glutamate receptor-4 increases maturation and survival of oligodendro-
cytes. Front. Cell. Neurosci. 8:462. doi: 10.3389/fncel.2014.00462
This article was submitted to the journal Frontiers in Cellular Neuroscience.
Copyright © 2015 Spampinato, Merlo, Chisari, Nicoletti and Sortino. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution and reproduction in other forums is permit-
ted, provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Cellular Neuroscience www.frontiersin.org January 2015 | Volume 8 | Article 462 | 11
